Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery
- 9 August 2013
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 115 (2) , 217-223
Abstract
To retrospectively evaluate the clinical benefit and imaging response of bevacizumab when used to treat refractory adverse radiation effects (ARE) after stereotactic radiosurgery. Twenty-nine patients with brain tumors or vascular malformations developed clinical and/or imaging evidence of ARE after SRS and were treated using bevacizumab. Patients received an average dose of 7.4 mg/kg over a mean of 5.7 weeks at a median of 16 months following SRS. Initial diagnosis, SRS dose, bevacizumab treatment protocols, magnetic resonance imaging T2/FLAIR and T1 paramagnetic contrast enhanced edema volumes were compared before and after bevacizumab administration. Ninety percent (18/20) with clinically symptomatic ARE had neurological improvement after bevacizumab therapy. Twenty-six patients had a decrease of 62 % of T2/FLAIR volumes and a 50 % decrease in magnetic resonance imaging intravenous contrast enhancement volumes. Two patients showed progression of the T2/FLAIR and contrast enhancement volumes. One patient had progression of post-Gd-enhancement but regression of T2/FLAIR volume. Symptoms recurred in 11 of the 20 patients after discontinuing therapy. Patients who experienced a return of enhancement received a lower marginal dose during SRS. Our experience provides additional evidence that bevacizumab reduces both symptoms and reactive imaging changes in patients with ARE. After SRS, refractory ARE unresponsive to initial corticosteroids or other agents may benefit from a bevacizumab trial. The necessary duration and optimum dose of therapy is unknown and provides a further impetus to conduct a prospective trial.Keywords
This publication has 16 references indexed in Scilit:
- Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgeryJournal of Neurosurgery, 2012
- Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: Case report and review of the literatureClinical Neurology and Neurosurgery, 2011
- The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential rolesJournal of Neuro-Oncology, 2011
- Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous SystemInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Exacerbation of Cerebral Radiation Necrosis by BevacizumabJournal of Clinical Oncology, 2011
- Bevacizumab as a Treatment Option for Radiation-Induced Cerebral NecrosisStrahlentherapie und Onkologie, 2011
- Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 casesJournal of Neuro-Oncology, 2010
- T1/T2 Matching to Differentiate Tumor Growth From Radiation Effects After Stereotactic RadiosurgeryNeurosurgery, 2010
- Adverse Radiation Effects after Radiosurgery May Benefit from Oral Vitamin E and Pentoxifylline Therapy: A Pilot StudyStereotactic and Functional Neurosurgery, 2008
- Treatment of radiation‐induced nervous system injury with heparin and warfarinNeurology, 1994